Rainer Blasczyk is Full Professor of Transfusion Medicine and Head of the Institute of Transfusion Medicine and Transplant Engineering at Hannover Medical School (MHH), Hanover, Germany since 1998 as well as board member of the Transplantation Center at Hannover Medical School since 2019. He graduated in medicine from the Universities Bochum and Essen before completing postgraduate training at the Universities of Marburg, Essen, Duesseldorf and Berlin, where he started to work on Molecular Immunogenetics in 1993. After being appointed to his current position he initiated the research on transplant engineering.

Professor Blasczyk has a long term research interest in solid organ transplantation and transplantation immunology with a main focus on transplant tolerance and transplant engineering. His work centers around the alloimmune response in organ transplantation and therapeutic interventions to combat rejection and infection. This includes cellular and humoral immunotherapy as well as genetic and transplant engineering approaches to achieve transplantation tolerance.

Professor Blasczyk is founder and chairman of the Immunotherapy Foundation. He has been a member of the Advisory Board on Blood Products of the German Ministry of Health, President of the German Society of Immunogenetics (DGI) and the German Society of Transfusion Medicine and Immunohematology (DGTI) as well as a Board Member of the European Society of Immunogenetics (EFI). 

Education and Professional Activities

• 1981 - 1987
  Medical School, Universities of Bochum and Essen, Germany
   
• 1987 - 1988
  Research fellow and postgraduate training in Surgery, Dept. of Visceral Surgery, University of Marburg, Germany
   
• 1989 - 1991
  Research fellow and postgraduate training in Immunology, Institute of Immunology, University of Essen, Germany
   
• 1992 - 1993
  Research fellow and postgraduate training in Hematology and Oncology, Dept. of Hematology and Oncology, University of Düsseldorf
   
• 1993 - 1998
  Research group leader on Molecular Immunogenetics and postgraduate training in Transfusion Medicine, Institute of Transfusion Medicine, Humboldt-University of Berlin, Germany
   
• 1996
  Board Certification, Transfusion Medicine
   
• 1997
  Habilitation in Transfusion Medicine, Member of the Faculty and Senior Lecturer, Humboldt-University of Berlin, Germany
   
• Since 1998
  Full Professor of Transfusion Medicine and head of the Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany

 

Additional Activities

• 2001
  Founder and Chairman of the Scientific Advisory Board, Imusyn GmbH & Co. KG (Biotech)
   
• 2005
  Founder and chairman, Foundation of Immunotherapy
   
• 2006 - 2023
  Editorial Board, HLA (formerly known as Tissue Antigens; Wiley)
   
• 2006 – 2008
  President, German Society for Immunogenetics (DGI)
   
• 2007 – 2010
  Executive Board, European Federation for Immunogenetics (EFI)
   
• 2007 – 2014
  Scientific Advisory Board, Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Germany
   
• 2009 – 2019
  Scientific Advisory Board, European Federation for Immunogenetics (EFI)
   
• Since 2011
  Editorial Board, Transfusionsmedizin (Thieme)
   
• 2012 – 2014
  President, German Society for Immunogenetics (DGI)
   
• 2014 – 2018
  Management Board, Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Germany
   
• 2015 – 2016
  President, German Society for Transfusion Medicine and Immunohematology (DGTI)
   
• 2016 – 2019
  Advisory board on blood products, German Ministry of Health
   
• 2018 - 2022
  Chairman of the Management Board, Research Network Invisible Organs
   
• Since 2019
  Management Board, Transplantation Center at Hannover Medical School
   
• Since 2021
  International Advisory Board, Transplant Immunology Research Centre of Excellence at Koç University, Istanbul, Turkey
   
• Since 2022
  Co-founder and CEO, Allogenetics GmbH (Biotech)
   

Download PDF

His research aims to prevent transplant rejection by genetic allograft engineering. Professor Blasczyk is considered a pioneer in transplant engineering and highly specialized in the field of histocompatibility and immunogenetics. He is particularly interested in the genetic structure, molecular function and regulation of histocompatibility systems in order to identify therapeutic targets for graft engineering to substantially improve clinical outcome of transplantation. Professor Blasczyk has initiated the Research Network on Invisible Organs, a pioneering project on transplant engineering to combat organ rejection.

 

Research Fields

• Transplant Engineering
• Transplant Immunology
• Genetic Engineering

 

PubMed Rainer Blasczyk Publication list (PubMed-Link)
 

 

Professor Rainer Blasczyk, MD

Institute of Transfusion Medicine and Transplant Engineering
Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hanover, Germany

 +49 511 532 6700
 +49 511 532 2079
blasczyk.rainer@mh-hannover.de